GE Healthcare in collaboration with GlaxoSmithKline to develop improved data and information integration in drug discovery
GE Healthcare has announced an informatics collaboration agreement with GlaxoSmithKline (GSK) to enable GSK to integrate data from diverse internal and external sources in its drug discovery R and D process.
GSK will be able to use GeneticXchange's DiscoveryHub data and information integration software from GE Healthcare within its R and D areas of genetics, discovery and its centres of excellence for drug discovery and pre-clinical development.
This will help GSK to maximise its use of biological, chemical and clinical data generated from its own drug discovery research, and integrate it seamlessly with other third party and public databases.
GE Healthcare and GeneticXchange will work in collaboration with GSK in the design, development and support of the next generation of DiscoveryHub technology.
"Effective informatics enable drug researchers to address one of the most difficult challenges in life sciences: transforming data into knowledge," comments Nick Giannasi, head of informatics solutions at GE Healthcare. "DiscoveryHub will support GSK in the efficient use of the available biological and clinical data in its drug discovery research.
"Connecting data sources regardless of location and complexity, DiscoveryHub provides scientists with access to the data they need in order to make informed decisions quickly."
